{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:11:31Z","timestamp":1780614691830,"version":"3.54.1"},"reference-count":40,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2022,9,30]]},"DOI":"10.1536\/ihj.21-859","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T22:11:15Z","timestamp":1663107075000},"page":"970-977","source":"Crossref","is-referenced-by-count":5,"title":["A Case of Infantile Mitochondrial Cardiomyopathy Treated with a Combination of Low-Dose Propranolol and Cibenzoline for Left Ventricular Outflow Tract Stenosis"],"prefix":"10.1536","volume":"63","author":[{"given":"Hironori","family":"Shimozawa","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Osaka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhito","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Omika","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Yada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Murayama","sequence":"additional","affiliation":[{"name":"Center for Medical Genetics and Department of Metabolism, Chiba Children&apos;s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Diagnostics and Therapeutic of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Kishita","sequence":"additional","affiliation":[{"name":"Diagnostics and Therapeutic of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University"},{"name":"Department of Life Science, Faculty of Science and Engineering, Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yamagata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wallance DC. Diseases of the mitochondrial DNA. Annu Rev Biochem 1992; 61: 1175-212.","DOI":"10.1146\/annurev.bi.61.070192.005523"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Leonard JV, Schapira AH. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 2000; 355: 299-304.","DOI":"10.1016\/S0140-6736(99)05225-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bates MG, Bourke JP, Giordano C, d&apos;Amati G, Turnbull DM, Taylor RW. Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur Heart J 2012; 33: 3023-33.","DOI":"10.1093\/eurheartj\/ehs275"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 2003; 24: 280-8.","DOI":"10.1016\/S0195-668X(02)00387-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Honzik T, Tesarova M, Magner M, <i>et al<\/i>. Neonatal onset of mitochondrial disorders in 129 patients: clinical and laboratory characterisitics and a new approach to diagnosis. J Inherit Metab Dis 2012; 35: 749-59.","DOI":"10.1007\/s10545-011-9440-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sugimoto M, Manabe H, Nakau K, <i>et al<\/i>. The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children. -Correlation with the heart failure score and comparison with B-type natriuretic peptide-. Circ J 2010; 74: 998-1005.","DOI":"10.1253\/circj.CJ-09-0535"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Galera-Monge T, Zurita-Diaz F, Garesse R, Gallardo ME. The mutation m.13513G&gt;A impairs cardiac function, favoring a neuroectoderm commitment, in a mutant-load dependent way. J Cell Physiol 2019; 234: 19511-22.","DOI":"10.1002\/jcp.28549"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Imai-Okazaki A, Kishita Y, Kohda M, <i>et al<\/i>. Cardiomyopathy in children with mitochondrial disease: prognosis and genetic background. Int J Cardiol 2019; 279: 115-21.","DOI":"10.1016\/j.ijcard.2019.01.017"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Blok MJ, Spruijt L, de Coo IF, Schoonderwoerd K, Hendrickx A, Smeets HJ. Mutations in the ND5 subunit of complex I of the mitochondrial DNA are a frequent cause of oxidative phosphorylation disease. J Med Genet 2007; 44: e74.","DOI":"10.1136\/jmg.2006.045716"},{"key":"10","first-page":"95","volume":"19","year":"2015","unstructured":"10. Brecht M, Richardson M, Taranath A, Grist S, Thorburn D, Bratkovic D. Leigh syndrome caused by the MT-ND5 m.13513G&gt;A mutation: a case presenting with WPW-like conduction defect, cardiomyopathy, hypertension and hyponatraemia. JIMD reports 2015; 19: 95-100.","journal-title":"JIMD Reports","ISSN":"https:\/\/id.crossref.org\/issn\/2192-8304","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Chol M, Lebon S, Benit P, <i>et al<\/i>. The mitochondrial DNA G13513A MELAS mutation in the NADH dehydrogenase 5 gene is a frequent cause fo Leigh-like syndrome with isolated complex I deficiency. J Med Genet 2003; 40: 188-91.","DOI":"10.1136\/jmg.40.3.188"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Corona P, Antozzi C, Carrara F, <i>et al<\/i>. A novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients. Ann Neurol 2001; 49: 106-10.","DOI":"10.1002\/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kirby DM, Boneh A, Chow CW, <i>et al<\/i>. Low mutant load of mitochondrial DNA G13513A mutation can cause Leigh&apos;s disease. Ann Neurol 2003; 54: 473-8.","DOI":"10.1002\/ana.10687"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Monlleo-Neila L, Toro MD, Bornstein B, <i>et al<\/i>. Leigh syndrome and the mitochondrial m.13513G&gt;A mutation: expanding the clinical spetrum. J Child Neurol 2013; 28: 1531-4.","DOI":"10.1177\/0883073812460580"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Petruzzella V, Di Giacinto G, Scacco S, <i>et al<\/i>. Atypical Leigh syndrome associated with the D393N mutation in the mitochondrial ND5 subunit. Neurology 2003; 61: 1017-8.","DOI":"10.1212\/01.WNL.0000080363.10902.E9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ruiter EM, Siers MH, van den Elzen C, <i>et al<\/i>. The mitochondrial 13513G&gt;A mutation is most frequent in Leigh syndrome combined with reduced complex I activity, optic atrophy and\/or Wolff-Parkinson-White. Eur J Hum Genet 2007; 15: 155-61.","DOI":"10.1038\/sj.ejhg.5201735"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Shanske S, Coku J, Lu J, <i>et al<\/i>. The G13513A mutation in the ND5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome: evidence from 12 cases. Arch Neurol 2008; 65: 368-72.","DOI":"10.1001\/archneurol.2007.67"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sudo A, Honzawa S, Nonaka I, Goto Y. Leigh syndrome caused by mitochondrial DNA G13513A mutation: frequency and clinical features in Japan. J Hum Genet 2004; 49: 92-6.","DOI":"10.1007\/s10038-003-0116-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wang SB, Weng WC, Lee NC, Hwu WL, Fan PC, Lee WT. Mutation of mitochondrial DNA <i>G13513A<\/i> presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr Neonatol 2008; 49: 145-9.","DOI":"10.1016\/S1875-9572(08)60030-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ommen SR, Mital S, Burke MA, <i>et al<\/i>. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary. A report of the American College of Cardiology\/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142: e533-57.","DOI":"10.1161\/CIR.0000000000000945"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Gwathmey JK, Warren SE, Briggs GM, <i>et al<\/i>. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 1991; 87: 1023-31.","DOI":"10.1172\/JCI115061"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Palmiter KA, Solaro RJ. Molecular mechanisms regulating the myofilament response to Ca2+: implications of mutations causal for familial hypertrophic cardiomyopathy. Basic Res Cardiol 1997; 92: 63-74.","DOI":"10.1007\/BF00794070"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hamada M, Aono J, Ikeda S, <i>et al<\/i>. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles. Circ J 2007; 71: 1540-4.","DOI":"10.1253\/circj.71.1540"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hamada M, Ikeda S, Ohshima K, <i>et al<\/i>. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy. J Cardiol 2016; 67: 279-86.","DOI":"10.1016\/j.jjcc.2015.05.014"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ostmam-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999; 34: 1813-22.","DOI":"10.1016\/S0735-1097(99)00421-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Takada M, Shibakawa M. Efficacy of therapeutic drug monitoring in prevention of hypoglycemia caused by cibenzoline. Eur J Clin Pharmacol 2001; 57: 695-700.","DOI":"10.1007\/s00228-001-0381-x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mukai Y, Wada K, Fujimoto M, Hosomi K, Kuwahara T, Takada M. Long-term impact of therapeutic drug monitoring on the risk of hypoglycemia in HOCM patients on cibenzoline therapy. Int J Clin Pharmacol Ther 2016; 54: 795-803.","DOI":"10.5414\/CP202655"},{"key":"28","unstructured":"28. Sekido Y, Amari S, Fujino S, Wada Y, Ono H, Ito Y. Hypertrophic cardiomyopathy with characteristic changes in myocardial thickness since fetal period: a case report. J Jpn Soc Perin Neon Med 2018; 54: 234-8 (Japanese)."},{"key":"29","unstructured":"29. Omori I, Shimizu M, Watanabe T. An infant with Costello syndrome and a rare <i>HRAS<\/i> mutation (G12C). J Jpn Pediatr Soc 2010; 114: 1592-7 (Japanese)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Takahashi K, Kogaki S, Kurotobi S, <i>et al<\/i>. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. Eur J Pediatr 2005; 164: 497-500.","DOI":"10.1007\/s00431-005-1679-y"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Doi T, Toritsuka D, Higashida A, Yokoyama S, Fukahara K, Yoshimura N. Concomitant septal myectomy and mitral valve repair in a child with Noonan syndrome. Clin Case Rep 2021; 9: 367-70.","DOI":"10.1002\/ccr3.3531"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ishikawa T, Iwashima S, Ohzeki T. Effect of cibenzoline on biventricular pressure gradients in a pediatric patient with hypertrophic obstructive cardiomyopathy. Pediatr Cardiol 2010; 31: 707-10.","DOI":"10.1007\/s00246-010-9651-7"},{"key":"33","unstructured":"33. Sakurai K, Soneda S, Kurihara Y, <i>et al<\/i>. Case report - a rare combination of hypertrophic obstructive cardiomyopathy and coronary artery dilatation in LEOPARD syndrome. J Jpn Pediatr Soc 2013; 117: 1792-6 (Japanese)."},{"key":"34","unstructured":"34. Yamazawa H, Murakami T, Ueno M, Takeda A, Yakuwa S. Response to cibenzoline in a child with hypertrophic cardiomyopathy. Pediatr Cardiol Card Surg 2006; 22: 648-52 (Japanese)."},{"key":"35","unstructured":"35. Meyers DE, Basha HI, Koenig MK. Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management. Tex Heart Inst J 2013; 40: 385-94."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Taylor GP. Neonatal mitochondrial cardiomyopathy. Pediatr Dev Pathol 2004; 7: 620-4.","DOI":"10.1007\/s10024-004-5050-5"},{"key":"37","unstructured":"37. Takeda A. Mitochondrial cardiomyopathy. J Pediatr Cardiol Card Surg 2020; 4: 53-62."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS\/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 2008; 29: 992-1006.","DOI":"10.1002\/humu.20748"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Nakaoka Y, Nishida K, Fujio Y, <i>et al<\/i>. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding\/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ Res 2003; 93: 221-9.","DOI":"10.1161\/01.RES.0000085562.48906.4A"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Ramos-Kuri M, Meka SH, Salamanca-Buentello F, Hajiar RJ, Lipskaia L, Chemaly ER. Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies. Biol Res 2021; 54: 23.","DOI":"10.1186\/s40659-021-00342-6"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/5\/63_21-859\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:25:48Z","timestamp":1715232348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/5\/63_21-859\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.21-859","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"21-859"}}